for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Amryt Pharma Holdings Ltd

AMYT.L

Latest Trade

195.00GBp

Change

0.00(0.00%)

Volume

5,718

Today's Range

--

 - 

--

52 Week Range

80.00

 - 

250.00

As of on the London Stock Exchange (LON) ∙ Minimum 15 minute delay

Pricing

Previous Close
195.00
Open
195.00
Volume
5,718
3M AVG Volume
2.90
Today's High
--
Today's Low
--
52 Week High
250.00
52 Week Low
80.00
Shares Out (MIL)
162.73
Market Cap (MIL)
319.39
Forward P/E
-58.81
Dividend (Yield %)
--

Next Event

Amryt Pharma Holdings Ltd at Leerink CybeRx Series: Rare Diseases & Genetic Medicines (Virtual)

Latest Developments

More

Amryt Pharma Holdings Q2 Diluted EPS Loss $0.12

Amryt Pharma Files Preliminary Prospectus Related To Listing Of 32.6 Mln ADSS On The Nasdaq

Amryt Pharma Says Publicly Files Registration Statement For Impending U.S. Listing On Nasdaq

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Amryt Pharma Holdings Ltd

Amryt Pharma Holdings Limited, formerly Amryt Pharma plc, is a commercial-stage specialty pharmaceutical company focused on developing and delivering treatments for patients with rare and orphan diseases. The Company is building a diversified portfolio of proprietary drugs to help address some of rare and debilitating illnesses. Its products include AP 101 and AP102. AP101 (Episalvan) is a potential treatment for Epidermolysis Bullosa (EB), and it is in Phase III clinical trials. AP102 is focused on developing novel, next generation somatostatin analogue (SSA) peptide medicines for patients with rare neuroendocrine diseases. It holds a license to sell Lojuxta (lomitapide) for adults, across the European Union (EU) and other territories, including the Middle East, North Africa, Turkey and Israel. Lojuxta is used to treat a rare life-threatening disease called Homozygous Familial Hypercholesterolemia.

Industry

Biotechnology & Drugs

Contact Info

Ivybridge House, 1 Adam Street

WC2N 6LE

United Kingdom

+44.20.34155730

https://www.amrytpharma.com/

Executive Leadership

Harry Thomas Stratford

Non-Executive Independent Chairman of the Board

Joe Wiley

Chief Executive Officer, Executive Director

Rory Nealon

Chief Financial Officer, Chief Operating Officer, Executive Director, Company Secretary

James Culverwell

Senior Non-Executive Independent Director

Ray Stafford

Non-Executive Independent Director

Key Stats

1.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019

0.1K

2020(E)

0.2K
EPS (USD)

2017

-0.504

2018

-0.413

2019

-0.510

2020(E)

-0.039
Price To Earnings (TTM)
--
Price To Sales (TTM)
2.91
Price To Book (MRQ)
4.66
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
224.64
LT Debt To Equity (MRQ)
224.51
Return on Investment (TTM)
-41.35
Return on Equity (TTM)
-32.55

Latest News

Latest News

Amryt Pharma's Filsuvez succeeds in rare skin disease trial

Amryt Pharma said Filsuvez, a topical therapeutic gel, had demonstrated a significant increase in speed of wound healing in the rare disease Epidermolysis Bullosa (EB) in a late-stage trial, the first treatment to do so.

Britain's Amryt Pharma raises profile with Nasdaq listing

Amryt Pharma <AMYT.L> <AMYT.O>, a rare disease specialist listed on London's AIM and Dublin's ESM markets, debuted on Nasdaq on Wednesday in a move aimed at increasing the liquidity of its stock and gaining more analyst coverage.

BRIEF-Amryt Pharma Files Preliminary Prospectus Related To Listing Of 32.6 Mln ADSS On The Nasdaq

* AMRYT PHARMA PLC FILES PRELIMINARY PROSPECTUS RELATED TO LISTING OF 32.6 MILLION ADSS ON THE NASDAQ - SEC FILING

BRIEF-Amryt Pharma Says Publicly Files Registration Statement For Impending U.S. Listing On Nasdaq

* AMRYT PHARMA PLC - AMRYT PUBLICLY FILES REGISTRATION STATEMENT FOR IMPENDING US LISTING ON NASDAQ

BRIEF-Amryt Pharma Signs Of Distribution Agreement With Swixx Biopharma AG

* ANNOUNCES SIGNING OF DISTRIBUTION AGREEMENT WITH SWIXX BIOPHARMA AG

BRIEF-Amryt Pharma Says COVID-19 Impact To Date Has Been Minimized

* AMRYT PHARMA HOLDINGS LTD - $44.6M UNAUDITED Q1 REVENUES REPRESENTING A 30% INCREASE ON UNAUDITED COMBINED REVENUES OF $34.3M IN Q1 2019

BRIEF-Amryt Pharma Says It Does Not Expect Significant Changes To Existing Revenues Due To Of Covid-19

* AMRYT PHARMA HOLDINGS LTD - BUSINESS PERFORMANCE IN Q4 2019 WAS STRONG AND THIS POSITIVE MOMENTUM HAS CONTINUED INTO Q1 2020

BRIEF-Amryt Pharma Announces Draft Registration Statement For U.S. Nasdaq Listing

* AMRYT PHARMA PLC - DRAFT REGISTRATION STATEMENT FOR US NASDAQ LISTING

UK's Amryt Pharma unites lomitapide franchise with Aegerion deal

Britain's Amryt Pharma has agreed to buy Aegerion Pharmaceuticals, a subsidiary of Novelion Therapeutics, in a deal that reunites the franchise for lomitapide, a treatment for patients with a rare cholesterol disorder.

BRIEF-Amryt Pharma Says FY ‍Revenue Increased To 12.8 Mln Euros

* REVENUES FOR YEAR ENDED 31 DECEMBER 2017 INCREASED TO EUR 12.8M (2016: EUR 1.48M) Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Blocktrade - Amryt Pharma says placing to raise EUR 15.0 million

* BLOCKTRADE - AMRYT PHARMA PLC : PLACING TO RAISE EUR 15.0 MILLION (£13.3 MILLION) THROUGH ISSUANCE OF 66,477,651 NEW ORDINARY SHARES AT 20 PENCE PER SHARE

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up